Bestmade Natural Products Manganese Sulfate (mang Sulf)

The dosage of Manganese varies significantly depending on whether it is being used for general nutritional maintenance or as part of a clinical intervention. For healthy adults, the Institute of Medicine (IOM) has established an Adequate Intake (AI) level rather than a Recommended Dietary Allowance (RDA).

• General Maintenance (Oral): The AI for adult men is 2.3 mg per day, and for adult women, it is 1.8 mg per day. Most individuals achieve this through a balanced diet containing nuts, legumes, and whole grains.
• Total Parenteral Nutrition (TPN): For adults receiving intravenous nutrition, the typical dose ranges from 0.15 mg to 0.8 mg per day. This is added to the TPN bag by a pharmacist according to the physician's orders.
• Therapeutic Supplementation: In specific cases of documented deficiency or as part of a bone-health regimen, healthcare providers may prescribe 5 mg to 10 mg per day. Doses exceeding the Tolerable Upper Intake Level (UL) of 11 mg per day should only be taken under strict medical supervision.

Pediatric dosing is strictly based on age and weight to prevent toxicity, as children are more susceptible to the neurological effects of Manganese accumulation.

• Infants (0-6 months): AI is approximately 0.003 mg per day.
• Infants (7-12 months): AI is approximately 0.6 mg per day.
• Children (1-3 years): AI is 1.2 mg per day.
• Children (4-8 years): AI is 1.5 mg per day.
• Adolescents (9-13 years): 1.9 mg per day for boys; 1.6 mg per day for girls.
• Adolescents (14-18 years): 2.2 mg per day for boys; 1.6 mg per day for girls.

In pediatric TPN, the dose is generally calculated as 1 microgram per kilogram of body weight per day (1 mcg/kg/day), not to exceed 50 mcg per day. Talk to a pediatrician before giving any Manganese-containing supplement to a child.

Renal Impairment

Because Manganese is primarily excreted through the bile and feces, renal impairment (kidney disease) typically does not require a significant dose adjustment. However, patients on dialysis should still be monitored, as systemic mineral balances can be delicate.

Hepatic Impairment

This is the most critical area for dosage adjustment. Patients with cholestasis (interrupted bile flow), cirrhosis, or other forms of liver dysfunction are at a high risk of Manganese toxicity because the body cannot effectively clear the mineral. In many cases, Manganese is omitted entirely from the TPN solutions of patients with significant liver disease to prevent brain accumulation.

Elderly Patients

No specific age-related dose adjustments are required for the elderly, provided liver function is normal. However, healthcare providers should consider the higher prevalence of polypharmacy and potential for underlying hepatic insufficiency in this population.

For oral supplements, Manganese should ideally be taken with a full glass of water. While it can be taken with food, high-fiber meals or foods rich in phytates (like beans and grains) may reduce absorption. Conversely, taking it on a completely empty stomach may cause mild nausea in some individuals. If you are taking other minerals like Iron or Calcium, it is often recommended to space the doses by at least 2 hours to prevent competition for absorption sites.

For injectable forms used in TPN, the administration is handled by healthcare professionals. The solution must be diluted and should never be given as a direct intravenous bolus (rapid injection).

If you miss a dose of an oral Manganese supplement, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this increases the risk of gastrointestinal upset or mineral imbalance.

Acute Manganese overdose from oral supplements is rare due to the body's low absorption rate. However, chronic over-supplementation or excessive intravenous administration can lead to severe toxicity. Signs of overdose include:

• Severe nausea and vomiting
• Metallic taste in the mouth
• Neurological changes (tremors, difficulty walking, mask-like facial expression)
• Extreme irritability or "manganese madness" (psychiatric disturbances)

In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment usually involves discontinuing the source of Manganese and, in severe cases, chelation therapy, although the efficacy of chelation for Manganese is limited once it has entered the brain.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

When taken at recommended dietary levels or standard TPN doses, Manganese is generally well-tolerated. However, some individuals may experience mild gastrointestinal effects, especially when starting oral supplements. These include:

• Nausea: A feeling of sickness in the stomach, often occurring if the supplement is taken on an empty stomach.
• Abdominal Cramping: Mild discomfort or tightening in the stomach area.
• Diarrhea: Loose or watery stools, which typically resolve as the body adjusts to the supplement.

These symptoms are usually transient and do not require medical intervention unless they persist or worsen.

Some patients may experience more noticeable reactions, particularly if they are sensitive to mineral salts:

• Constipation: Difficulty passing stools, which can sometimes occur with mineral supplementation.
• Metallic Taste: A lingering copper or iron-like taste in the mouth (dysgeusia).
• Loss of Appetite: A temporary reduction in the desire to eat.
• Headache: Mild to moderate tension-type headaches.

Rarely, Manganese can cause more systemic issues, often related to individual hypersensitivity or underlying metabolic conditions:

• Skin Rash: Itching or redness of the skin (dermatitis).
• Dizziness: A sensation of spinning or lightheadedness.
• Insomnia: Difficulty falling or staying asleep, sometimes associated with very high doses.

Serious side effects from Manganese are almost exclusively associated with chronic toxicity (manganism) or excessive intravenous administration.

> Warning: Stop taking Manganese and call your doctor immediately if you experience any of these symptoms, which may indicate neurological accumulation:

• Parkinsonian Tremors: Involuntary shaking of the hands, arms, or legs, often occurring at rest.
• Bradykinesia: Slowness of movement, making simple tasks like walking or dressing difficult.
• Muscle Rigidity: Stiffness in the limbs or trunk that is not explained by exercise.
• Postural Instability: Difficulty maintaining balance or a tendency to fall.
• Psychiatric Changes: Sudden onset of irritability, aggression, hallucinations, or emotional lability (often referred to as "locura manganica").
• Mask-like Face: A decrease in facial expressions, giving the face a fixed or "stony" appearance.
• Slurred Speech: Difficulty articulating words clearly (dysarthria).

These symptoms represent serious neurological damage to the basal ganglia and require immediate clinical evaluation, including MRI imaging and blood Manganese level testing.

The primary concern with long-term Manganese use, particularly at doses above the Tolerable Upper Intake Level (11 mg/day for adults), is the gradual accumulation of the metal in the brain. Unlike many other minerals, Manganese has a very slow clearance rate from the central nervous system. Over years, this can lead to permanent neurological impairment that mimics Parkinson's disease but does not respond well to standard Parkinson's medications like Levodopa.

Additionally, long-term excessive intake may interfere with the absorption of other essential minerals, potentially leading to a secondary iron deficiency or zinc imbalance. Regular monitoring of mineral status is recommended for anyone on high-dose long-term therapy.

Currently, there are no FDA black box warnings for Manganese. However, the FDA does require specific warning labels on parenteral Manganese products regarding the risk of toxicity in patients with liver disease or those receiving long-term TPN. These warnings emphasize that Manganese should be used with extreme caution in patients with biliary obstruction or significant hepatic insufficiency.

Report any unusual symptoms to your healthcare provider. Monitoring of blood levels is the best way to ensure long-term safety.

Manganese is an essential nutrient, but it occupies a narrow therapeutic window, meaning the difference between an adequate dose and a toxic dose can be small, especially in vulnerable populations. Patients should be aware that Manganese is found in many multi-vitamin products, and cumulative intake from multiple sources can exceed safe limits. It is also important to note that Manganese toxicity can occur through inhalation (e.g., in industrial welding or mining settings), which can compound the risks of oral or intravenous supplementation.

No FDA black box warnings for Manganese. However, clinical guidelines from organizations like ASPEN (American Society for Parenteral and Enteral Nutrition) provide strong cautionary advice regarding its use in parenteral nutrition, particularly for patients with liver dysfunction.

• Neurological Risk: The most significant precaution involves the risk of neurotoxicity. Manganese has a predilection for the globus pallidus and other structures of the basal ganglia. Once deposited, it is difficult to remove. Patients with existing neurological disorders should use Manganese supplements only under strict supervision.
• Hepatotoxicity and Biliary Obstruction: Because the liver and bile are the only significant pathways for Manganese excretion, any condition that impairs bile flow (cholestasis) or liver function (cirrhosis, hepatitis) creates a massive risk for Manganese buildup. In such patients, even standard doses can become toxic.
• Anemia and Iron Deficiency: Patients with iron-deficiency anemia tend to absorb more Manganese because the body upregulates the transport proteins (DMT1) used by both minerals. This increased absorption can inadvertently lead to Manganese toxicity while the patient is attempting to treat their anemia.
• Allergic Reactions: While rare, hypersensitivity to Manganese salts can occur. Symptoms of an allergic reaction include hives, difficulty breathing, and swelling of the face, lips, or tongue. If anaphylaxis is suspected, seek emergency care immediately.

For patients on long-term Manganese therapy or TPN, healthcare providers typically order the following tests:

• Whole Blood Manganese Levels: This is the most common way to monitor status, though it does not always perfectly correlate with tissue stores.
• Liver Function Tests (LFTs): To ensure the biliary excretion pathway is functioning correctly. This includes testing Bilirubin, Alkaline Phosphatase, ALT, and AST.
• Neurological Exams: Periodic assessment of motor function and gait, especially in patients receiving intravenous Manganese for more than 30 days.
• MRI Imaging: In cases of suspected toxicity, a T1-weighted MRI of the brain can show characteristic hyperintensities in the basal ganglia, indicating Manganese deposition.

Standard doses of Manganese do not typically affect the ability to drive or operate machinery. However, if a patient begins to experience early signs of toxicity, such as dizziness, tremors, or slowed reaction times, they should refrain from these activities and consult their doctor immediately.

There is no direct contraindication between Manganese and moderate alcohol consumption. However, chronic excessive alcohol use can lead to liver damage (cirrhosis), which significantly impairs the body's ability to excrete Manganese. Patients with alcohol-related liver disease should avoid Manganese supplements unless specifically directed by a physician.

For most people taking oral supplements, Manganese can be stopped abruptly without withdrawal symptoms. However, for patients on TPN, Manganese levels are usually tapered or adjusted by the medical team based on lab results. If you are taking Manganese to treat a specific deficiency, stopping it suddenly may cause the deficiency symptoms to return over time.

> Important: Discuss all your medical conditions with your healthcare provider before starting Manganese, especially if you have a history of liver disease or neurological issues.

There are no drugs that are absolutely contraindicated with Manganese in the sense of causing an immediate lethal reaction. However, Manganese should not be administered intravenously in the same line as certain alkaline solutions or medications that can cause precipitation.

From a clinical standpoint, Manganese supplementation is contraindicated in patients with severe biliary obstruction, as the inability to excrete the mineral will lead to rapid and dangerous accumulation in the brain.

• Antipsychotic Medications (e.g., Haloperidol, Risperidone): Manganese toxicity can cause extrapyramidal symptoms (tremors, rigidity) that are very similar to the side effects of antipsychotic drugs. Using Manganese supplements alongside these medications may increase the risk or severity of movement disorders. Healthcare providers should monitor for additive neurological effects.
• Levodopa: While Manganese toxicity mimics Parkinson's, it does not respond to Levodopa. In fact, some evidence suggests that high Manganese levels might interfere with the efficacy of Levodopa in patients who actually have Parkinson's disease.
• Ethambutol: This tuberculosis medication can occasionally cause neurological side effects. Combining it with high-dose Manganese may complicate the clinical picture and increase neurotoxic risks.

• Quinolone Antibiotics (e.g., Ciprofloxacin, Levofloxacin): Manganese can bind to these antibiotics in the gut, forming a complex that the body cannot absorb. This reduces the effectiveness of the antibiotic. It is recommended to take Manganese at least 2 hours before or 4 to 6 hours after these medications.
• Tetracycline Antibiotics (e.g., Doxycycline): Similar to quinolones, Manganese can chelate tetracyclines, reducing their bioavailability. Doses should be separated by several hours.
• Iron Supplements: Manganese and Iron compete for the same absorption pathways (DMT1). High doses of one can inhibit the absorption of the other. Patients needing both should ideally take them at different times of the day.
• Calcium and Magnesium Supplements: These divalent cations can also compete with Manganese for absorption, though the interaction is generally less significant than with Iron.

• Phytic Acid (Phytates): Found in whole grains, legumes, and nuts, phytates can bind to Manganese in the digestive tract and significantly reduce its absorption.
• Oxalic Acid (Oxalates): Found in spinach, rhubarb, and sweet potatoes, oxalates may also interfere with Manganese uptake.
• Tannins: Found in tea and coffee, tannins can inhibit the absorption of many minerals, including Manganese.
• High-Fiber Diets: Very high fiber intake can speed up intestinal transit and provide more binding sites for minerals, potentially lowering Manganese levels.

• Zinc Supplements: High doses of Zinc can interfere with Manganese absorption and vice versa. Long-term use of one should be balanced with the other.
• St. John's Wort: While no direct chemical interaction exists, St. John's Wort can affect liver enzymes. Although Manganese isn't metabolized by these enzymes, the overall impact on liver health should be considered.

• MRI Contrast Agents: Manganese itself is paramagnetic. High levels of Manganese in the blood or brain can interfere with the interpretation of MRI scans, particularly T1-weighted images, as it can mimic the appearance of certain contrast agents or pathologies.
• Liver Function Tests: While Manganese doesn't usually change the test results directly, Manganese toxicity is often associated with elevated bilirubin or alkaline phosphatase due to the underlying liver issues that caused the toxicity.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to ensure a comprehensive safety review.

There are specific clinical scenarios where Manganese supplementation or administration must be avoided entirely:

• Severe Biliary Obstruction: Because Manganese is almost exclusively eliminated through the bile, a complete blockage of the bile ducts (such as from a tumor or severe gallstones) will cause Manganese levels to rise to toxic levels rapidly. This can lead to irreversible brain damage.
• Hypersensitivity: Any known allergy to Manganese salts (such as Manganese Sulfate or Manganese Chloride) is an absolute contraindication. Although rare, allergic reactions can be severe.
• Existing Manganism: If a patient already shows signs of Manganese-induced neurotoxicity, further supplementation is strictly prohibited.

Relative contraindications require a careful risk-benefit analysis by a healthcare professional:

• Mild to Moderate Hepatic Impairment: Patients with cirrhosis or hepatitis have a reduced capacity to clear Manganese. If supplementation is necessary (e.g., in TPN), doses must be significantly reduced and blood levels monitored frequently.
• Iron Deficiency Anemia: While not a contraindication for Manganese in small amounts, patients with low iron levels absorb Manganese much more efficiently. High-dose supplements should be used cautiously in these patients to prevent accidental toxicity.
• Parkinson's Disease: Since Manganese toxicity can worsen or mimic movement disorders, patients with Parkinson's should avoid supplemental Manganese unless a deficiency is clearly documented.
• Children and Infants: Due to their developing nervous systems and different biliary clearance rates, Manganese must be dosed with extreme precision in pediatric populations.

There is little evidence of cross-sensitivity between Manganese and other minerals. However, patients who have had allergic reactions to other mineral salts (like Magnesium or Zinc) should be monitored closely when starting Manganese, as the inactive ingredients or the salt forms (like sulfates or gluconates) may be shared between products.

> Important: Your healthcare provider will evaluate your complete medical history, including liver function and neurological health, before prescribing Manganese.

Manganese is an essential nutrient during pregnancy, playing a role in the skeletal development of the fetus and the mother's metabolic health. It is classified as generally recognized as safe (GRAS) when consumed within the Adequate Intake (AI) limits.

• FDA Pregnancy Category: Not formally assigned, but it is considered essential at nutritional doses.
• Risks: Both deficiency and excess can be harmful. Manganese deficiency during pregnancy has been linked in animal studies to skeletal abnormalities and impaired growth. However, excessive Manganese exposure (particularly from environmental sources) has been associated with neurodevelopmental issues in offspring.
• Dosing: The AI for pregnant women is 2.0 mg per day. Pregnant women should avoid high-dose supplements unless specifically directed by their obstetrician.

Manganese is a natural component of breast milk, though its concentration is relatively low compared to infant formula.

• Passage into Milk: Manganese does pass into breast milk, but the concentrations are tightly regulated by the mother's body.
• Infant Safety: The AI for lactating women is 2.6 mg per day. There is no evidence that standard nutritional doses are harmful to the nursing infant. However, mothers with liver disease or those exposed to high environmental levels of Manganese should be cautious, as their milk levels could potentially be elevated.

Manganese is critical for growth and bone development in children. However, the pediatric population is uniquely vulnerable to Manganese toxicity.

• Approved Use: It is approved for use in pediatric TPN and as a dietary supplement.
• Growth Effects: While essential for bone growth, excessive Manganese can interfere with the absorption of other nutrients like iron, which is also critical for a child's development.
• Toxicity Risk: Children absorb a higher percentage of Manganese than adults and have less efficient biliary excretion mechanisms. Symptoms of toxicity in children may manifest as learning disabilities or behavioral changes rather than the classic motor symptoms seen in adults.

Older adults generally have the same Manganese requirements as younger adults, but several factors necessitate caution:

• Renal/Hepatic Decline: While renal decline is less impactful for Manganese, the gradual decrease in hepatic reserve in some elderly patients can slow Manganese clearance.
• Polypharmacy: The elderly are more likely to be taking medications (like antipsychotics or antibiotics) that can interact with Manganese.
• Fall Risk: If Manganese toxicity occurs, the resulting tremors and balance issues significantly increase the risk of falls and fractures in the geriatric population.

In patients with kidney disease, Manganese is generally considered safe at standard doses because the kidneys are not the primary route of excretion. However, in patients with end-stage renal disease (ESRD) on dialysis, systemic mineral balances are easily disrupted. Monitoring is advised, but aggressive dose reduction is usually not required unless liver function is also compromised.

This is the most critical special population for Manganese.

• Child-Pugh Classification: Patients with Child-Pugh Class B or C (moderate to severe liver disease) should generally not receive supplemental Manganese, especially via the intravenous route.
• Monitoring: If Manganese must be given to a patient with liver disease, whole blood levels should be checked at least monthly, and the clinician should have a low threshold for performing an MRI if any neurological symptoms emerge.

> Important: Special populations require individualized medical assessment to balance the need for this essential mineral against the risks of accumulation.

Manganese functions primarily as a catalytic cofactor for a diverse group of enzymes. Its ability to exist in multiple oxidation states (Mn2+, Mn3+, Mn4+) allows it to participate in redox reactions and stabilize protein structures.

• Antioxidant Activity: As the core of Mitochondrial Superoxide Dismutase (MnSOD), Manganese facilitates the dismutation of superoxide radicals (O2-) into oxygen and hydrogen peroxide, protecting the mitochondria—the cell's power plant—from oxidative stress.
• Metabolic Regulation: Manganese activates pyruvate carboxylase, which is the rate-limiting enzyme in gluconeogenesis. It also serves as a cofactor for phosphoenolpyruvate carboxykinase (PEPCK).
• Urea Cycle: It is a required component of arginase, the enzyme that converts arginine to urea and ornithine, a vital step in detoxifying nitrogenous waste.
• Connective Tissue Synthesis: Manganese activates glycosyltransferase enzymes, which are essential for the formation of chondroitin sulfate, a major component of bone and cartilage.

The pharmacodynamics of Manganese are characterized by a strict homeostatic control mechanism in healthy individuals. The body maintains stable tissue levels through a combination of low intestinal absorption and rapid biliary excretion. There is no known "onset of action" for Manganese as a nutrient; rather, its effects are cumulative and related to the maintenance of enzymatic pools. Tolerance to Manganese does not develop, but the risk of toxicity increases linearly with the bypass of the GI tract (as in TPN) or the failure of the biliary system.

| Parameter | Value |

|---|---|

| Bioavailability | 1% - 5% (Oral) |

| Protein Binding | 80% - 95% (Albumin, Transferrin) |

| Half-life | 13 - 37 days |

| Tmax | 1 - 2 hours (Oral) |

| Metabolism | None (Elemental) |

| Excretion | Fecal (>95% via Bile); Renal (<1%) |

Manganese is a chemical element with the symbol Mn and atomic number 25. It is a hard, brittle, silvery-gray transition metal. In supplements, it is usually provided as a salt. For example, Manganese Sulfate (MnSO4) has a molecular weight of 151.00 g/mol and is highly soluble in water. Manganese Gluconate (C12H22MnO14) has a molecular weight of 445.23 g/mol. These salts dissociate in the digestive tract to release the active Mn2+ ion.

Manganese is classified as a Trace Element and a Micronutrient. Within the USP and FDA classification systems, it is often listed under Electrolytes and Nutritional Supplements. It is related to other essential trace minerals such as Copper, Zinc, and Selenium, which are also frequently included in parenteral nutrition and multi-mineral formulations.